Rashmi K. Murthy

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-0103-4718

发表论文 264 篇 · 总被引 7205 次 · h-index 33

代表论文

• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial (2025 · JCO Precision Oncology · 被引 5)
• Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study (2025 · Breast Cancer Research · 被引 4)
• Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results (2026 · Nature Cancer · 被引 1)
• Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial (2026 · Nature Communications)
• MMDA-18 CLINICAL OUTCOMES WITH SACITUZUMAB GOVITECAN IN BREAST CANCER-ASSOCIATED LEPTOMENINGEAL METASTASIS (2026 · Neuro-Oncology Advances)
• Trastuzumab-deruxtecan for the management of leptomeningeal metastases from breast cancer. (2026 · Journal of Clinical Oncology)